Panitumumab Pricing “Bookends” Will Be Avastin, Erbitux, Amgen Says
Executive Summary
Amgen's pending oncologic panitumumab will be priced between Genentech's Avastin and Bristol-Myers Squibb/ImClone's Erbitux, Exec VP-Commercial Operations George Morrow said